We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Stellar Presents Preclinical Poster on C. diff Active Immunotherapy
News

Stellar Presents Preclinical Poster on C. diff Active Immunotherapy

Stellar Presents Preclinical Poster on C. diff Active Immunotherapy
News

Stellar Presents Preclinical Poster on C. diff Active Immunotherapy

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Stellar Presents Preclinical Poster on C. diff Active Immunotherapy"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Stellar Biotechnologies, Inc. has announced the presentation of a preclinical poster at the 7th Vaccine and ISV Congress being held in Sitges, Spain, October 27-29, 2013.

The presentation relates to a recent study in mice of Stellar’s newly acquired active immunotherapy technology targeting the treatment of Clostridium difficile infection (“C. diff”).

Clostridium difficile is a bacteria found in the intestines that can cause severe and life-threatening intestinal conditions. C. diff infections are at an all-time high and related hospitalizations have tripled in the last decade.

The poster titled “Immunization with Clostridium difficile PSII Polysaccharide Antigens Adjuvanted with KLH Induced Broad-based Enhancement of Adaptive Immune Responses and Protection in Mice” is the result of preclinical research conducted together by scientists from Stellar and the University of Guelph (Ontario, Canada) (“Guelph”).

In the study, vaccination with a PSII-KLH conjugate vaccine conferred protection against C. diff infection, measured by improved survival rates in vaccinated mice compared to unvaccinated controls.

The study concluded that the C. diff PSII-KLH immunotherapy approach was safe and efficacious in a preclinical model. Further preclinical development is underway.

The 7th Vaccine & ISV Congress features science and public health topics, from primary vaccine research and vaccine manufacturers, to governmental policy, safety and regulation.

Advertisement